Regeneron Pharmaceuticals Inc (REGN)

Return on equity (ROE)

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income	US$ in thousands	4,412,600	3,953,600	4,338,400	8,075,300	3,513,200
Total stockholders’ equity	US$ in thousands	29,353,600	25,973,100	22,664,000	18,768,800	11,025,300
ROE		15.03%	15.22%	19.14%	43.03%	31.86%

December 31, 2024 calculation

ROE = Net income ÷ Total stockholders’ equity
= $4,412,600K ÷ $29,353,600K
= 15.03%

Regeneron Pharmaceuticals Inc's return on equity (ROE) has shown fluctuating trends over the years based on the provided data. In December 31, 2020, the ROE stood at 31.86%, indicating that for every dollar of shareholders' equity, the company generated a profit of 31.86 cents.

There was a significant increase in the ROE by December 31, 2021, reaching 43.03%. This suggests that the company became more efficient in utilizing its shareholders' equity to generate profits within a year.

However, there was a notable decline in ROE by December 31, 2022, dropping to 19.14%. This could be a result of various factors such as increased expenses or a slowdown in revenue growth.

The trend continued with a further decrease in ROE by December 31, 2023, down to 15.22%. This indicates that the company's profitability in relation to equity investment decreased compared to the previous year.

By December 31, 2024, the ROE remained relatively stable at 15.03%, suggesting that the company has been able to maintain its profitability levels with respect to shareholders' equity.

Overall, it is essential for Regeneron Pharmaceuticals Inc to analyze the factors influencing these fluctuations in ROE to ensure sustainable and consistent profitability for its shareholders.